Back to Search
Start Over
UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes.
- Source :
-
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Mar; Vol. 128, pp. 7-16. Date of Electronic Publication: 2020 Mar 05. - Publication Year :
- 2020
-
Abstract
- Background: Concurrent chemoradiotherapy is the standard treatment for anal cancer. Following national UK implementation of intensity-modulated radiotherapy (IMRT), this prospective, national cohort evaluates the one-year oncological outcomes and patient-reported toxicity outcomes (PRO) after treatment.<br />Materials and Methods: A national cohort of UK cancer centers implementing IMRT was carried out between February to July 2015. Cancer centers provided data on oncological outcomes, including survival, and disease and colostomy status at one-year. EORTC-QLQ core (C30) and colorectal (CR29) questionnaires were completed at baseline and one-year followup. The PRO scores at baseline and one year were compared.<br />Results: 40 UK Cancer Centers returned data with a total of 187 patients included in the analysis. 92% received mitomycin with 5-fluorouracil or capecitabine. One-year overall survival was 94%; 84% were disease-free and 86% colostomy-free at one-year followup. At one year, PRO results found significant improvements in buttock pain, blood and mucus in stools, pain, constipation, appetite loss, and health anxiety compared to baseline. No significant deteriorations were reported in diarrhea, bowel frequency, and flatulence. Urinary symptom scores were low at one year. Moderate impotence symptoms at baseline remained at one year, and a moderate deterioration in dyspareunia reported.<br />Conclusions: With national anal cancer IMRT implementation, at this early pre-defined time point, one-year oncological outcomes were reassuring and resulted in good disease-related symptom control. one-year symptomatic complications following CRT for anal cancer using IMRT techniques appear to be relatively mild. These PRO results provide a basis to benchmark future studies.<br />Competing Interests: Declaration of competing interest None declared.<br /> (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols adverse effects
Anus Neoplasms mortality
Diarrhea diagnosis
Diarrhea epidemiology
Diarrhea etiology
Disease-Free Survival
Dose Fractionation, Radiation
Dose-Response Relationship, Radiation
Dyspareunia diagnosis
Dyspareunia epidemiology
Dyspareunia etiology
Erectile Dysfunction diagnosis
Erectile Dysfunction epidemiology
Erectile Dysfunction etiology
Female
Flatulence diagnosis
Flatulence epidemiology
Flatulence etiology
Follow-Up Studies
Humans
Male
Middle Aged
Organs at Risk radiation effects
Prospective Studies
Radiation Injuries diagnosis
Radiation Injuries etiology
Severity of Illness Index
United Kingdom epidemiology
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Anus Neoplasms therapy
Patient Reported Outcome Measures
Radiation Injuries epidemiology
Radiotherapy, Intensity-Modulated adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0852
- Volume :
- 128
- Database :
- MEDLINE
- Journal :
- European journal of cancer (Oxford, England : 1990)
- Publication Type :
- Academic Journal
- Accession number :
- 32109852
- Full Text :
- https://doi.org/10.1016/j.ejca.2019.12.022